CLEC1A

Across TCGA pan-cancer cohorts, CLEC1A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLEC1A data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLEC1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC1A expression acts as an unfavorable survival marker.

HNSC, LUSC, and COAD are the cancer types where CLEC1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.710	.002	24	view →
LUSC	OS	Median	All	0.081	0.818	<.001	9	view →
COAD	DFS	Median	II,III,IV	0.074	0.744	<.001	3	view →
KIRP	DFS	Median	All	0.508	0.919	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLEC1A–HNSC (OS)

Open the HNSC breakdown →